Belantamab mafodotin-blmf (Blenrep) demonstrated comparable antitumor toxicity across three dose levels in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) in patients with transplant-ineligible, newly diagnosed... [10160 chars].. reed more
